- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06046040
TmPSMA-02 in mCRPC
Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design as described below. Dose escalation will begin with Dose Level 1 as follows:
Dose Level 1 (N = 3 to 6): Subjects will receive a single dose of 5 x 107 TmPSMA-02 CAR T cells via IV infusion administration on Day 0, following lymphodepletion with fludarabine and cyclophosphamide. This dose level will be evaluated as follows:
- If 1 DLT/3 subjects occurs, the study will enroll an additional 3 subjects at this dose level.
- If 0 DLT/3 subjects or 1 DLT/6 subjects occur, the study will advance to Dose Level 2 (DL2).
- In the event that 2 or more DLTs occur at Dose Level 1 (DL1), enrollment at this dose level will be stopped and Dose Level -1 (DL-1) will be opened. In Dose Level -1, subjects will receive a de-escalated dose of 1 x 107 TmPSMA-02 CAR T cells following lymphodepletion.
If 0 DLT/3 or 1 DLT/3 subjects occurs at DL-1, the study will enroll an additional 3 subjects at this dose level.
If ≥ 2 DLTs occur at any time, enrollment at this dose level will be stopped.
Dose Level 2 (N = 3 to 6): Subjects will receive a single fixed dose of 1 x 108 TmPSMA-02 CAR T cells via IV infusion on Day 0, following lymphodepletion with fludarabine and cyclophosphamide. This dose level will be evaluated as follows:
- If 1 DLT/3 subjects occurs, the study will enroll an additional 3 subjects at this dose level.
- If 0 DLT/3 subjects or 1 DLT/6 subjects occur, the study will advance to Dose Level 3 (DL3).
If 2 DLTs occur at any time, enrollment at this dose level will be stopped. If less than 6 subjects were treated at the previous dose level (DL1), additional subjects will be enrolled at that dose level to reach a minimum of 6 DLT-evaluable subjects for MTD determination.
• Dose Level 3 (N = 3 to 6): Subjects will receive a single fixed dose of 3 x 108 TmPSMA-02 CAR T cells via IV infusion Day 0, following lymphodepletion with fludarabine and cyclophosphamide. This dose level will be evaluated as follows:
- If 1 DLT/3 subjects occurs, the study will enroll an additional 3 subjects at this dose level.
- If 0 DLT/3 subjects occurs, the study will still enroll an additional 3 subjects at this dose level to allow for MTD determination.
- If 2 DLTs occur at any time, enrollment at this dose level will be stopped. If less than 6 subjects were treated at the previous dose level (DL2), additional subjects will be enrolled at that dose level to reach a minimum of 6 DLT-evaluable subjects for MTD determination.
The highest dose at which 0 or 1 DLT occurs in 6 DLT-evaluable subjects will be declared the MTD.
Retreatment Infusions:
The Retreatment Phase will remain closed until sufficient safety and persistence data is available in initial subjects, and DSMB and FDA approval to open Retreatment has been received.
Subjects who have demonstrated clinical benefit after their initial TmPSMA-02 CAR T cell infusion (e.g., minimum disease response of stable disease, etc.) may also be eligible to receive retreatment with TmPSMA-02 CAR T cells at the physician-investigator's discretion. The TmPSMA-02 retreatment dose administered must either be a) the CAR T cell dose that the subject previously received without DLTs, or b) a CAR T cell dose that is less than or equal to a dose level that has been evaluated for safety in ≥ 3 other subjects without evidence of DLTs. As retreatment infusions will not be used for formal DLT assessments/MTD determination, there are no protocol-defined staggering requirements.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Abramson Cancer Center Clinical Trials Service
- Phone Number: 8552160098
- Email: PennCancerTrials@careboxhealth.com
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Abramson Cancer Center of the University of Pennsylvania
-
Contact:
- Vivek Narayan, MD, MSCE
- Phone Number: 855-216-0098
- Email: PennCancerTrials@careboxhealth.com
-
Principal Investigator:
- Vivek Narayan, MD, MSCE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed, written informed consent
- Adult participants ≥ 18 years of age
- Metastatic castrate-resistant prostate cancer (mCRPC)
- Castrate levels of testosterone (<50 ng/dL) with/without the use of androgen-deprivation therapy
- Received at least one prior standard therapy for systemic treatment in the mCRPC setting, including at least one second generation androgen receptor signaling inhibitor (e.g., enzalutamine, apalutamide, darolutamide, or abiraterone) or a taxane-based regimen (e.g., docetaxel, cabazitaxel, etc).
Adequate organ function within 4 weeks of eligibility confirmation by a physician-investigator defined as:
- Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 50 cc/min per the Cockcroft-Gault Equation; Patient must not be on dialysis
- ALT/AST ≤ 3 x ULN
- Serum total bilirubin ≤ 1.5 mg/dL, unless the subject has Gilbert's syndrome (if so, serum total bilirubin must be ≤3.0 mg/dL)
- Left Ventricle Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO
- Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air
Patients must have adequate hematologic reserve within 4 weeks of eligibility confirmation by a physician-investigator and must not be dependent on transfusions to maintain these hematologic parameters. Adequate hematologic reserve is defined as:
- Hemoglobin ≥ 8 g/dL
- Absolute neutrophil count ≥ 1000/μL
- Platelet count ≥ 75,000/μL
- ECOG Performance Status that is either 0 or 1.
- Patients who have not undergone bilateral orchiectomy must be able to continue GnRH therapy during the study.
- Participants of reproductive potential must agree to use acceptable birth control methods, as described in the protocol.
Exclusion Criteria:
- Active hepatitis B or hepatitis C infection
- Any other active, uncontrolled infection
- Class III/IV cardiovascular disability according to the New York Heart Association Classification.
- Severe, active co-morbidity that in the opinion of the physician-investigator would preclude participation in the study.
- Active invasive cancer, other than the proposed cancer included in the study, within 2 years prior to eligibility confirmation by a physician-investigator. [Note: non-invasive cancers treated with curative intent (e.g., non-melanoma skin cancer) may still be eligible].
- Patients requiring chronic treatment systemic steroids or immunosuppressant medications. Low-dose physiologic replacement therapy with corticosteroids equivalent to prednisone 10 mg/day or lower, topical steroids and inhaled steroids are acceptable. For additional details regarding use of steroid and immunosuppressant medications, please see Section 5.6.
- Prior treatment with autologous T-cell therapy, with the exception of Sipuleucel-T.
- Prior allogeneic stem cell transplant.
- Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
- History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level -1
After lymphodepleting chemotherapy subjects to receive 1x10(7) TmPSMA-02 CAR T Cells
|
TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
|
Experimental: Dose Level 1
After lymphodepleting chemotherapy subjects to receive 5 x10(7) TmPSMA-02 CAR T Cells
|
TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
|
Experimental: Dose Level 2
After lymphodepleting chemotherapy subjects to receive 1x10(8) TmPSMA-02 CAR T Cells
|
TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
|
Experimental: Dose Level 3
After lymphodepleting chemotherapy subjects to receive 3x10(8) TmPSMA-02 CAR T Cells
|
TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events as assessed by CTCAE v5.0
Time Frame: Up to 15 years
|
Up to 15 years
|
Number of subjects with dose limiting toxicities (DLTs)
Time Frame: 28 days after TmPSMA-02 CAR T cell infusion
|
28 days after TmPSMA-02 CAR T cell infusion
|
Determination of maximum tolerated dose (MTD)
Time Frame: 28 days after TmPSMA-02 CAR T cell infusion
|
28 days after TmPSMA-02 CAR T cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of manufacturing products that meet release criteria
Time Frame: Up to 3 years
|
Up to 3 years
|
Overall Survival (OS)
Time Frame: Up to one year
|
Up to one year
|
Progression Free Survival (PFS)
Time Frame: Up to one year
|
Up to one year
|
Overall Response Rate (ORR)
Time Frame: Up to 3 months
|
Up to 3 months
|
Duration of Response (DOR)
Time Frame: up to one year
|
up to one year
|
Percent Change in PSA from Baseline
Time Frame: Up to one year
|
Up to one year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 11823
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
-
Suzhou Kintor Pharmaceutical Inc,CompletedMetastatic Castrate Resistant Prostate Cancer (mCRPC)United States
-
University of Texas Southwestern Medical CenterCompletedmCRPC | Metastatic Castrate-resistant Prostate CancerUnited States
-
Suzhou Kintor Pharmaceutical Inc,CompletedMetastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)United States
-
BayerRecruitingMetastatic Castrate Resistant Prostate Cancer (mCRPC)Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
-
AstraZenecaCompletedMetastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.United Kingdom, United States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
GenesisCare USADendreonCompletedCastrate Refractory Metastatic Prostate Cancer (mCRPC)United States
-
British Columbia Cancer AgencyRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate CancerCanada
-
IpsenTerminatedMetastatic Castrate Resistant Prostate CancerFrance, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Clinical Trials on TmPSMA-02 CAR T Cells
-
Tceleron Therapeutics, Inc.TerminatedMetastatic Castration-resistant Prostate CancerUnited States
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina